【79.rtt469.top】

오션우주 전함 야마토 2205무료 릴게임백경 게임

오리지날게임 ㅟ 39.rtt469.top ㅟ 바다이야기 사이트

오리지날게임 ㅟ 35.rtt469.top ㅟ 바다이야기 사이트

오리지날게임 ㅟ 88.rtt469.top ㅟ 바다이야기 사이트

오리지날게임 ㅟ 11.rtt469.top ㅟ 바다이야기 사이트

야마토사이트 바다이야기 먹튀사이트 릴게임종류 오리지날황금성 무료슬롯사이트 중고게임기 매매 바다이야기앱 황금성9 모바일 바다 이야기 다운 뉴야마토 꽁머니릴게임 릴게임바다이야기 신천지게임하는곳 일본야마토 사이다쿨게임 황금성먹튀 빠찡코 유니티 슬롯 머신 릴게임골드몽릴게임 강원랜드슬롯머신 야마토게임방법 신천지게임랜드 슬롯머신 코딩 야마토게임장 릴게임 다빈치 황금성게임 오션파라 다이스예시 pc빠찡꼬게임 황금성게임다운로드 황금성나비 온라인바다이야기게임 우주 전함 야마토 2205 슬롯머신 규칙 바다이야기게임사이트 황금성게임방법 릴게임 무료머니 파칭코게임다운로드 바다이야기pc 무료머니릴게임 야마토하는법 야마토게임장주소 온라인바다이야기 모바일오션파라다이스7 황금성3 슬롯 무료체험 오션파다라이스 다운로드 무료 바다이야기 야마토노하우 슬롯 게임사 추천 바다이야기 황금고래 황금성3게임다운로드 프라그마틱환수율 릴게임갓 프라그마틱 무료체험 카지노 슬롯머신 규칙 바다이야기황금고래 황금포카성 바다이야기공략법 손오공 릴게임 바다이야기 상어 릴게임무료 슬롯게임 하는법 바다이야기파칭코 유희왕 황금성 무료 슬롯 머신 카지노 게임 온라인배경 잘터지는 슬롯 pc야마토 무료야마토 한국파친코 인터넷손오공게임 황금성릴 양귀비게임설명 바다이야기5 오락실게임 파라다이스 바다이야기 꽁 머니 환전 바다이야기 무료머니 알라딘게임잭팟 무료 야마토게임 알라딘다운로드 황금성게임종류 바다이야기 게임기 릴게임손오공 바다슬롯 먹튀 황금성공략법 신규슬롯사이트 슬롯머신 하는법 오리지날야마토2게임 야마토게임공략방법 포커게임사이트 체리마스터 확률 게임몰릴게임 바다이야기시즌5 안전 검증 릴게임 사이다쿨 야마토5 인터넷빠찡꼬 야마토하는곳 온라인황금성주소 모바일파칭코 슬롯 무료체험 프라그마틱 체험 슬롯 추천 디시 릴게임손오공게임 바다이야기사이트 야마토동영상 jQuery 슬롯 머신 야마토온라인주소 해적게임 야마토무료게임 손오공 바다 이야기 다운 온라인신천지게임 오션파라 다이스게임다운로드 슬롯머신게임 알라딘게임잭팟 황금성3 바다이야기넥슨 우주전함야마토2199 야마토게임 하기 신오션파라다이스 오션파라다이스7하는곳 슬롯무료체험 오션파라다이스7 다모아릴게임 This article was released as Pharm Edaily Premium Content on April 25, 2025, at 7:42 AM.


[Kim Jiwan, Edaily Reporter] On the 24th, Korea’s biopharmaceutical sector surged, fueled by news of successful U.S. clinical trials and the unveiling of next-generation technologies.
HK inno.N hit the upper limit after its gastroesophageal reflux disease (GERD) treat 가계일반자금대출 ment K-CAB (Tegoprazan) showed outstanding results in its U.S. Phase 3 trial. Inventage Lab and Curatis also surged on expectations surrounding their oral obesity drug development. Geninus rose for th 휴학생대출 e second consecutive day, buoyed by rumors of a major contract.
According to KG Zeroin’s MP DOCTOR (formerly MarketPoint), HK inno.N’s stock hit the upper limit of KRW 48,900 immediately aft 롯데카드 er market open and closed at that price. Geninus rose 14.05% to KRW 1,534, driven by large investors following contract rumors. Inventage Lab saw its stock hit the upper limit amid buzz over its weekl lh신혼부부전세임대 y oral obesity drug, which is said to have up to 70 times better absorption than those from Eli Lilly and Novo Nordisk. Curatis, which is majority-owned by Inventage Lab, also hit its upper limit in t 창업지원센터 andem.
HK inno.N Soars on U.S. Phase 3 Results for K-CAB
HK inno.N reported that its GERD treatment K-CAB (Tegoprazan) met both primary and secondary endpoints in two U.S. Phase 3 clinical trials (TRIUMpH), according to its U.S. partner Sebela.
In the trial for erosive esophagitis, K-CAB demonstrated superiority over Takeda’s Lansoprazole in healing rates at weeks 2 and 8, with statistically significant results. In the non-erosive GERD trial, K-CAB showed complete symptom relief for both heartburn (including nighttime heartburn) and acid reflux.



HK inno.N K-CAB.


A company official highlighted praise from Dr. Felice Schnoll-Sussman of Weill Cornell Medical College and Dr. Prateek Sharma, president of the American Society for Gastrointestinal Endoscopy. They commended K-CAB’s differentiated efficacy, not only in relieving heartburn but also in reducing acid reflux?an effect not seen with other treatments.
Adverse events occurred in less than 3% of patients and were mostly mild and transient. Serious adverse events occurred in fewer than 2% of participants, with no significant differences between the Tegoprazan, PPI, and placebo groups.
Sebela plans to complete an additional Phase 3 trial on maintenance therapy for erosive esophagitis by Q3 this year.
Geninus: Institutional Buying on Contract Rumors
Geninus’ sharp stock rise over two consecutive days was largely attributed to institutional buying.
On April 22, its trading volume was a mere KRW 22 million. But on April 23, trading value surged by 21,468% to KRW 4.7 billion, and on the 24th, it more than doubled again to KRW 9.9 billion.



Woong-Yang Park, CEO of Geninus and Director of the Samsung Genome Institute at Samsung Medical Center, is interviewed by Edaily at the company‘s headquarters on Jeongui-ro, Songpa-gu, Seoul, in February. (Photo by Jiwan Kim)


While Geninus stated there was no specific news behind the spike, sources from the investment banking (IB) industry pointed to impending contracts in both Korea and Japan. A source indicated that talks were also ongoing with several small-to-medium-sized pharmaceutical firms and that early contracts could serve as a catalyst for broader deals with large pharma companies in the second half of the year.
Geninus acknowledged that while it couldn‘t disclose details, it is planning to offer solutions to pharmaceutical companies.
Inventage Lab & Curatis Hit Upper Limit on Next-Gen Obesity Drug Momentum
Inventage Lab and its affiliate Curatis both hit their upper price limits. Inventage Lab became Curatis’ largest shareholder earlier this year through a KRW 25 billion investment, acquiring 15.9 million shares and convertible bonds, giving it a 40% stake.



Their rally was sparked by recent news that Eli Lilly had succeeded in a Phase 3 trial for the world’s first oral GLP-1-based obesity treatment, Orforglipron. This reignited momentum around oral obesity drugs.
On top of this, a media report released after the previous trading session claimed that Inventage Lab had achieved what neither Lilly nor Novo Nordisk could: a “7-day sustained-release oral obesity drug” with 70 times better absorption.
Using its proprietary platform IVL-GeneFluidic, Inventage Lab demonstrated a stable 7-day pharmacokinetic (PK) profile in beagle models, compared to under 24 hours for existing drugs. The company reported an oral absorption rate of approximately 24% over 70 times higher than Novo Nordisk’s Rybelsus (which is less than 1%).
An Inventage Lab official stated the results would be presented at the upcoming American Diabetes Association (ADA) meeting this year and added that licensing talks with global pharmaceutical firms were already underway.
According to Morgan Stanley, the global obesity treatment market is expected to grow from USD 8.9 billion (approx. KRW 12.75 trillion) in 2024 to USD 54 billion (approx. KRW 77.36 trillion) by 2030.
김지완 (2pac@edaily.co.kr)